Aap Implantate Ag · XETR:AAQ1
Aap Implantate — Q3 2018 Earnings Presentation
10 slides from Aap Implantate's earnings presentation, Nov 14, 2018
Slide 1: aap Implantate AG Q3/9M 2018 Report Conference Call
aap Implantate AG Q3/9M 2018 Report Conference Call Bruke Seyoum Alemu, CEO Marek Hahn, CFO Berlin, November 14, 2018
Slide 2: Safe Harbor Statement
Safe Harbor Statement Our publication may include predictions, estimates or other information that might be considered forward-looking. While these forward-looking statements represent our current judgment on what the future holds, they are subject to risks and uncertainties that could cause actual
Slide 3: Key results and progress Q3/2018 and 9M/2018
Key results and progress Q3/2018 and 9M/2018 ➢ Sales and Earnings ▪ Q3 sales (EUR 2.7 million) and EBITDA (EUR -1.5 million) in line with guidance ▪ Q3 trauma sales +7% yoy, 9M trauma sales +6% yoy ▪ Continued positive development in focus market Germany (+8% yoy in Q3, +12% yoy in 9M) and internati
Slide 4: Key results and progress Q3/2018 and 9M/2018
Key results and progress Q3/2018 and 9M/2018 ➢ LOQTEQ® ▪ Working on European approval of various polyaxial LOQTEQ® systems ▪ Development of sterile packaging for implants ▪ Adaption of processes and documents to new regulatory requirements ▪ Approval applications submitted to FDA (foot and periprost
Slide 5: Financial Figures Q3/2018
Financial Figures Q3/2018 (in KEUR) Sales (reported) Q3/2018 Q3/2017 Change Trauma 2,763 2,574 +7% Germany 688 639 +8% North America 536 733 -27% North America Distributors 529 625 -15% North America Global Partners 7 108 -94% International 1,539 1,202 +28% Other (mainly discontinued activities in F
Slide 6: Financial Figures 9M/2018
Financial Figures 9M/2018 (in KEUR) Sales (reported) 9M/2018 9M/2017 Change Trauma 8,238 7,785 +6% Germany 2,080 1,849 +12% North America 1,687 2,450 -31% North America Distributors 1,626 1,877 -13% North America Global Partners 61 573 -89% International 4,471 3,486 +28% Other (mainly discontinued a
Slide 7: Highlights 9M/2018 (Balance Sheet)
Highlights 9M/2018 (Balance Sheet) ➢ Total assets 09/30/2018: EUR 44.6 million (12/31/2017: EUR 50.5 million) -12% ▪ Non-current assets: almost unchanged, but countervailing effects Capitalized development costs: EUR +1.0 million Share of intangible assets in total assets: 29% Tangible asset
Slide 8: Highlights 9M/2018 (Cash Flow)
Highlights 9M/2018 (Cash Flow) ➢ Operating Cash Flow 9M/2018: EUR -3.7 million (9M/2017: EUR -4.4 million) ▪ Improved operating result (EBIT) ▪ Positive contribution from working capital of EUR 0.3 million reduction of inventory (EUR +0.3 million), increasing receivables (EUR -0.3 million) and inc
Slide 9: Outlook
Outlook FY/2018 – Sales: EUR 10.0 million – EUR 11.7 million (FY/2017: EUR 10.9 million) EBITDA: EUR -6.9 million – EUR -5.9 million (FY/2017: EUR -6.2 million) 9
Slide 10: Many thanks for your attention!
Many thanks for your attention! Lorenzweg 5 • 12099 Berlin • Germany Fabian Franke Manager Investor Relations Tel.: +49 30 750 19 – 134 Fax: +49 30 750 19 – 290 E-Mail: ir@aap.de IR-app: 10